Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MaxCyte, Inc

< Previous 1 2 Next >
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
From MaxCyte, Inc
Via GlobeNewswire
Tickers ASX:IMU MXCT
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Participate in Baird Global Healthcare Conference
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
MaxCyte Reports Third Quarter 2022 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Tickers MXCT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.